An independent guide to cash-pay care. Every price is dated and sourced.

How we check
Wellchosen HealthSearch

Compounded GLP-1 and peptide laws by state

Compounded semaglutide is legal in every state only in narrow cases set by federal law: a state-licensed pharmacy may make it for one patient when the prescriber documents a clinically significant difference from the FDA-approved drug, because FDA declared the semaglutide shortage over on Feb 21 2025[1].

Updated By the Wellchosen Health editorial team

No state action we found bans it outright or makes it broadly legal again; most states that acted issued board statements, consumer alerts or enforcement, and California's compounding rules are the clearest binding state rule[3]. The table gives every state and DC, with the source behind each cell and the date we checked.

A compounded GLP-1 is a semaglutide or tirzepatide product mixed by a pharmacy rather than made by the drug's maker; it is not FDA-approved, and FDA does not review it for safety, effectiveness or quality[2].

States with a GLP-1 compounding action
23 of 51, by our count of the table below (most are guidance or enforcement, not statutes)
503B outsourcing facilities
May not compound semaglutide or tirzepatide from bulk ingredients now; neither is on the shortage list or the 503B bulks list[1]
Telehealth and controlled drugs
Federal DEA flexibilities run through Dec 31 2026[6]

See GLP-1 self-pay prices

The federal rule every state starts from

States license pharmacies, but the limits on compounding semaglutide and tirzepatide come mostly from federal law. FDA says a 503A pharmacy may compound these drugs only for a named patient, and may not make “essentially copies” of an approved drug unless the prescriber documents a change that makes a significant difference for that patient. FDA has said it does not intend to act against a 503A pharmacy filling four or fewer copy prescriptions in a calendar month[1]. 503B outsourcing facilities cannot use bulk semaglutide or tirzepatide at all right now[1].

On Feb 6 2026 FDA said it intends to act against the ingredients used in non-approved compounded GLP-1s, and that ads cannot call compounded products generic, the same as approved drugs, or clinically proven[5]. Read more on compounded semaglutide, compounded tirzepatide and the FDA warning letter tracker.

A small clear medication vial with a silver cap on a linen table

Compounded GLP-1, peptide and Medicaid rules by state

State rules and actions on compounded GLP-1s and peptides, and Medicaid weight-loss coverage, checked Oct 24 2026
StateCompounded GLP-1 rules or actionsPeptide compounding actionsMedicaid GLP-1 for weight loss
AlabamaBoard of Medical Examiners declaratory ruling on physician compounding, Aug 8 2024. It reaches compounding in doctors' offices.[3]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[22]
AlaskaNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[23]
ArizonaHB 4036 (2026) would add sourcing, testing and advertising rules for compounded GLP-1s, with a $1,000 per dose civil penalty. It is introduced bill text, not law.[9]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[24]
ArkansasNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[25]
CaliforniaBoard of Pharmacy compounding rules, in effect since Oct 1 2025, bar making “essentially a copy” of a commercial drug except in a shortage or for a documented, clinically significant difference for one patient[7][3]. AB 1990, a GLP-1 sourcing and advertising bill, was held in committee on Aug 13 2026.[8]No state-specific peptide rule found (checked Oct 24 2026)[3]Ended in 2026 (Oct 18 2026)[26]
ColoradoSB26-066 would have regulated compounded GLP-1 sales, labels and ads. It passed the Senate on Apr 17 2026; its last recorded action was House committee assignment on Apr 20 2026, and it is not law.[10]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[27]
ConnecticutAttorney General settlements: on May 6 2026 a medspa agreed to stop advertising and selling compounded semaglutide and tirzepatide, after a similar June 2025 settlement[11]. The pharmacy regulator has taken no GLP-1 position.[3]May 6 2026 settlement: the Made-in-China platform agreed to stop sales of “research grade” GLP-1s into the US.[11]Not covered (Oct 18 2026)[28]
DelawareNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Covered (Oct 18 2026)[29]
District of ColumbiaNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not confirmed (Oct 18 2026)[30]
FloridaSB 860 (2026), which would have required documentation before selling compounded weight-loss drugs, died in committee on Mar 13 2026[12]. A board rule ties sterile compounding to the federal FD&C Act.[3]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[31]
GeorgiaNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[32]
HawaiiNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[33]
IdahoA May 29 2024 board letter said filling multiple syringes that are not for a named patient and sending them out can be dispensing and the practice of pharmacy (reported by a tracker; letter text not machine-readable).[4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not confirmed (Oct 18 2026)[34]
IllinoisAttorney General consumer alert, Jan 3 2025, plus five cease-and-desist letters to med spas over misleading claims.[13]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[35]
IndianaSB 282 (2026) was signed into law; it takes effect July 1 2026, and med spa registration is expected to start January 2027[14]. The Senate narrowed the bill to GLP-1 compounding[15]; a med spa trade group's article gives conflicting accounts of whether the compounding provisions stayed in the final law.[14]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[36]
IowaRule 481-552.22(2) bars compounding an essentially copy of an FDA-approved drug unless the prescriber documents a clinically significant change for the patient or the drug is in shortage. Effective date delayed in July 2025; delay lifted Aug 11 2025.[16]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[37]
KansasBoard of Pharmacy semaglutide statement, April 2024, and a GLP-1/GIP compounding guidance document.[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Covered (Oct 18 2026)[38]
KentuckyBoard FAQ: compounding a commercially available product such as semaglutide or tirzepatide is allowed only in narrow cases, and non-conforming compounding can draw board or FDA action[17]. HB 729 (2026) went to committee on Mar 4 2026 and did not pass.[18]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[39]
LouisianaNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[40]
MaineNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[41]
MarylandNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[42]
MassachusettsNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Ended in 2026 (Oct 18 2026)[43]
MichiganNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Covered with limits (Oct 18 2026)[44]
MinnesotaNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Covered (Oct 18 2026)[45]
MississippiSB 2544 (2026), a bulk-ingredient quality bill, died Feb 3 2026. The board links to FDA's current GLP-1 policy.[4]No state-specific peptide rule found (checked Oct 24 2026)[3]Covered (Oct 18 2026)[46]
MissouriNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Covered (Oct 18 2026)[47]
MontanaNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[48]
NebraskaNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[49]
NevadaNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[22]
New HampshireNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Ended in 2026 (Oct 18 2026)[50]
New JerseyBoard of Pharmacy statement on semaglutide compounding, Nov 6 2023.[3]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[51]
New MexicoNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[52]
New YorkNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[53]
North CarolinaBoard of Pharmacy compounding FAQ covers GLP-1 compounding after the shortage ended (undated).[4]No state-specific peptide rule found (checked Oct 24 2026)[3]Covered (Oct 18 2026)[54]
North DakotaNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[55]
OhioBoard guidance of July 17 2025 treats semaglutide and tirzepatide as no longer compoundable as copies and requires active ingredients from an Ohio-licensed distributor. The board reports summarily suspending more than 30 clinics and med spas since early 2025.[3]Board says retatrutide and cagrilintide cannot be used in compounding under federal and state law; licensees may face immediate suspension (August 2025).[19]Not covered (Oct 18 2026)[56]
OklahomaNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[57]
OregonBoard statement, adopted Feb 6 2025: copies are barred unless the drug is in shortage or a specific change is needed for a named patient; a lower price alone does not qualify; salt forms and “research use only” ingredients may not be used.[20]The semaglutide statement bars “research use only” ingredients in compounding (Feb 6 2025).[20]Not covered (Oct 18 2026)[58]
PennsylvaniaState Board of Pharmacy action, Oct 21 2025: a $1 million civil penalty and probation for one facility over about 30,000 doses. Not a statewide rule.[4]No state-specific peptide rule found (checked Oct 24 2026)[3]Ended in 2026 (Oct 18 2026)[59]
Rhode IslandNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Ended in 2026 (Oct 18 2026)[60]
South CarolinaAttorney General consumer alert, Jan 3 2025, on unapproved and compounded tirzepatide and semaglutide.[21]No state-specific peptide rule found (checked Oct 24 2026)[3]Ended in 2026 (Oct 18 2026)[61]
South DakotaBoard consumer notice, January 2024, on counterfeit products and semaglutide salt forms.[4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[62]
TennesseeNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Covered (Oct 18 2026)[63]
TexasNo state-specific rule found (checked Oct 24 2026). General pharmacy compounding rules apply; the board has no GLP-1 position.[3]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[64]
UtahDivision of Professional Licensing and Board notice on semaglutide compounding, May 2024.[4]No state-specific peptide rule found (checked Oct 24 2026)[3]Ended in 2026 (Oct 18 2026)[65]
VermontNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[66]
VirginiaNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Covered with limits (Oct 18 2026)[67]
WashingtonPharmacy Quality Assurance Commission statement on compounding semaglutide, Aug 22 2024; it later limited one pharmacy's license on Mar 13 2025.[3]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[68]
West VirginiaBoard of Pharmacy semaglutide statement, April 2023.[3]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[69]
WisconsinNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Covered with limits (Oct 18 2026)[70]
WyomingNo state-specific rule found (checked Oct 24 2026)[3][4]No state-specific peptide rule found (checked Oct 24 2026)[3]Not covered (Oct 18 2026)[71]
“No state-specific rule found” means we found no GLP-1 or peptide statute, rule, board statement or enforcement action in two state surveys and our own search on Oct 24 2026. Federal law and each state's general pharmacy, prescribing and consumer protection laws still apply. Medicaid status is from our Medicaid GLP-1 tracker, checked Oct 18 2026.

What most state actions look like

  • Board statements and FAQs. Oregon, Kentucky, New Jersey, Kansas, West Virginia and Washington restate the federal copy rule for their pharmacists[20][17][3].
  • Binding rules. California's board rules and Iowa's rule 481-552.22 write the copy limit into state regulation[7][16].
  • Enforcement. Ohio reports suspending more than 30 clinics and med spas since early 2025, and Pennsylvania fined one facility $1 million[3][4].
  • Attorney General action. Connecticut, Illinois and South Carolina used consumer protection law: settlements, cease-and-desist letters and alerts[11][13][21].
  • Bills that did not pass. Colorado SB26-066, Florida SB 860, Kentucky HB 729 and Mississippi SB 2544 did not become law in 2026, and California AB 1990 was held in committee[10][12][18][4][8].

Peptides: few states have acted

Almost every state that has taken a position did so on GLP-1 compounding, not on peptides in general, according to a 2026 law firm survey[3]. Ohio is the clear exception: its board says retatrutide and cagrilintide cannot be used in compounding under federal and state law[19]. FDA says the same of both ingredients[2]. Peptides sold as “research use only” are not legal medicine in any state; see research-use-only GLP-1s, retatrutide and the peptide legal status tracker.

Telehealth prescribing

Federal DEA flexibilities let DEA-registered clinicians prescribe controlled medicines by telemedicine without a prior in-person visit through Dec 31 2026[6]. Many states add their own rules on controlled medicines by telehealth. We have not checked those rules state by state for this edition, so the table has no telehealth column yet rather than a guess. Ask any online program whether its clinician is licensed in your state before you pay; our online GLP-1 program guide lists what to check.

How to check a compounded GLP-1 where you live

  1. Ask which pharmacy compounds the drug, and whether it is a 503A pharmacy or a 503B outsourcing facility[1].
  2. Look the pharmacy up with your state board of pharmacy, and check our FDA warning letter tracker for the seller.
  3. Ask the prescriber what clinically significant difference makes a compounded version right for you, since that is the legal basis FDA describes[1].
  4. Compare with FDA-approved options: brand Wegovy and Zepbound self-pay prices, and your state's Medicaid coverage.

Safety

FDA has received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31 2026, and has warned about dosing errors with compounded vials[2]. Severe stomach pain that will not go away, or signs of an allergic reaction, need care right away. In an emergency, call 911.

How we built this table

We started from two 2026 state surveys, one by a law firm and one by a drug-price research site[3][4], then opened the primary source (the rule, bill record, board statement or attorney general release) wherever it loaded on Oct 24 2026 and cited it directly. Where only a survey described a state action, the cell cites the survey. We update the page when a state acts; send corrections to the address on our contact page. Our editorial standards explain how we source pages.

Questions people ask

Is compounded semaglutide legal in my state?

In every state, only in narrow cases: a state-licensed 503A pharmacy may compound it for a named patient when the prescriber documents a clinically significant difference from the approved drug, because FDA declared the semaglutide shortage over on Feb 21 2025[1]. Some states add their own limits; the table on this page lists each one.

Is compounded tirzepatide legal?

Under the same narrow 503A rule as semaglutide. FDA declared the tirzepatide shortage resolved on Dec 19 2024, and 503B outsourcing facilities may not compound it from bulk ingredients[1].

Which states have the strictest compounded GLP-1 rules?

California and Iowa have written the federal copy limit into binding state rules, and Ohio requires active ingredients from an Ohio-licensed distributor and reports suspending more than 30 clinics and med spas since early 2025[7][16][3].

Has any state banned compounded GLP-1s?

We found no state ban as of Oct 24 2026. A law firm survey published Aug 6 2026 found that only California had enacted a GLP-1-relevant rule with the force of law; other states used statements, alerts or enforcement[3].

Are peptides like BPC-157 legal in my state?

Peptide legality is set mostly by federal compounding law, and few states have acted on peptides as a group, per an Aug 6 2026 survey[3]. Ohio bars compounding retatrutide and cagrilintide[19].

Can an online doctor in another state prescribe me a GLP-1?

Online programs generally need a clinician licensed where you are, and state rules differ. For controlled medicines, federal DEA telemedicine flexibilities run through Dec 31 2026[6]. GLP-1 rules by state for telehealth are not in this table yet.

Does Medicaid in my state cover GLP-1s for weight loss?

Most do not. The Medicaid column of this table gives each state's status as of Oct 18 2026; for example, North Carolina covers them and California ended adult weight-loss coverage in 2026[54][26].

Medical review: pending. A licensed clinician has not yet reviewed this page.

Sources

71 cited
  1. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration, Apr 1, 2026.
  2. FDA's concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, Oct 1, 2026.
  3. Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides. Sheppard Mullin, Aug 6, 2026.
  4. Compounded GLP-1 laws by state (tracker, version 1.1). The Rx Index, Aug 6, 2026.
  5. FDA intends to take action against non-FDA-approved GLP-1 drugs. U.S. Food and Drug Administration, Feb 6, 2026.
  6. HHS and DEA extend telemedicine flexibilities for prescribing controlled medications through 2026. Gordon Rees Scully Mansukhani, Oct 24, 2026.
  7. Order of adoption: compounded drug products (16 CCR 1735 to 1738.14). California State Board of Pharmacy, Jun 17, 2025.
  8. AB 1990: advertising certain compounded medications used for obesity or weight management. CalMatters Digital Democracy, Oct 24, 2026.
  9. HB 4036, 57th Legislature, 2nd Regular Session (introduced text). Arizona State Legislature, Oct 24, 2026.
  10. SB26-066: regulation of compounded weight-loss medication. Colorado General Assembly, Oct 24, 2026.
  11. Attorney General Tong announces online platform to cease bootleg weight loss drug sales. Connecticut Office of the Attorney General, May 6, 2026.
  12. SB 860 (2026): compounded drugs. The Florida Senate, Oct 24, 2026.
  13. Updated consumer alert: Attorney General Raoul reminds Illinois residents to be vigilant when seeking GLP-1 drugs for weight loss. Illinois Attorney General, Jan 3, 2025.
  14. Bill regulating Indiana med spas has passed: what you need to know. American Med Spa Association, Oct 24, 2026.
  15. Fight over GLP-1 compounding plays out in statehouses, courthouses. The Indiana Lawyer (Indianapolis Business Journal), Feb 25, 2026.
  16. Iowa Administrative Code 481, chapter 552 (rule 552.22, compounding). Iowa Legislature, Oct 24, 2026.
  17. Compounding FAQ: Can I compound GLP-1s, such as semaglutide and tirzepatide?. Kentucky Board of Pharmacy, Oct 24, 2026.
  18. HB 729 (2026 Regular Session) bill record. Kentucky General Assembly, Oct 24, 2026.
  19. Ohio State Board of Pharmacy newsletter, August 2025 (Vol. 46, No. 3). Ohio State Board of Pharmacy, Aug 2025.
  20. Statement on semaglutide (adopted Feb 6 2025). Oregon Board of Pharmacy, Feb 6, 2025.
  21. Consumer alert: Attorney General Alan Wilson warns consumers to be cautious when purchasing unapproved and compounded weight loss medications. South Carolina Attorney General, Jan 3, 2025.
  22. Medicaid GLP-1 coverage by state. The Rx Index, Sep 28, 2026.
  23. Semaglutide criteria, Version 2. Alaska Department of Health, Sep 18, 2026.
  24. AMPM 310-V: prescription medications and pharmacy services. AHCCCS, Oct 9, 2026.
  25. Arkansas Medicaid April 2026 DUR provider memo. Arkansas Medicaid (Prime Therapeutics), May 13, 2026.
  26. GLP-1 coverage considerations. Medi-Cal Rx (DHCS), Apr 6, 2026.
  27. Appendix P, effective Oct 1, 2026. Colorado HCPF, Oct 1, 2026.
  28. Connecticut state plan amendment 25-0014. CMS (Medicaid.gov), Jun 3, 2025.
  29. GLP-1 agonist for weight management, MASH or prevention of MACE: PA form. Delaware DHSS, Apr 20, 2026.
  30. District FFS pharmacy provider manual. DHCF (Prime Therapeutics), Aug 28, 2023.
  31. Final order 24-FH0081 quoting the Florida Medicaid Prescribed Drugs Coverage Policy. Florida Health Justice Project library, Apr 17, 2024.
  32. Georgia Medicaid PDL by drug class, Oct 1, 2026. Georgia DCH, Oct 1, 2026.
  33. SB 3195 (2026). Hawaii State Legislature, 2026.
  34. Idaho Medicaid preferred drug list. Idaho DHW, Jul 1, 2026.
  35. Illinois Medicaid preferred drug list, Oct 1, 2026. Illinois HFS, Oct 1, 2026.
  36. GLP-1 RA and GIP combination PA criteria. Indiana Medicaid (OptumRx), Dec 1, 2025.
  37. Incretin mimetics for non-diabetes indications: PA form 470-0058. Iowa Medicaid, Jan 2026.
  38. Anti-obesity medications PA criteria. Kansas KDHE, Aug 19, 2026.
  39. 907 KAR 23:010. Kentucky Legislature, Jul 22, 2024.
  40. SB 433 (2026 Regular Session), reengrossed. Louisiana State Legislature, 2026.
  41. Semaglutide for MACE reduction: PA form. MaineCare, Mar 2026.
  42. COMAR 10.09.03.05. Maryland Division of State Documents, Oct 18, 2026.
  43. MassHealth Pharmacy Facts 276. MassHealth, May 13, 2026.
  44. Numbered Letter L 25-73: pharmacy. Michigan MDHHS, Dec 8, 2025.
  45. Minnesota preferred drug list, Jan 1, 2026. Minnesota DHS, Jan 1, 2026.
  46. Anti-obesity select agents PA criteria, V11. Mississippi Division of Medicaid, Jul 1, 2026.
  47. GLP-1s for obesity: criteria proposal. Missouri DSS (MO HealthNet), Oct 14, 2025.
  48. Montana Medicaid pharmacy program. Montana DPHHS, Oct 18, 2026.
  49. Medicaid services. Nebraska DHHS, Oct 18, 2026.
  50. Notification: GLP-1 coverage change. New Hampshire Medicaid (Prime Therapeutics), Oct 9, 2025.
  51. N.J.A.C. 10:51 pharmaceutical services manual. New Jersey Department of Human Services, Jun 16, 2025.
  52. Weight reduction medications. New Mexico Health Care Authority, Mar 4, 2025.
  53. NYRx pharmacy policy guidelines, version 2026-3. New York State Department of Health (eMedNY), Sep 2026.
  54. NC Medicaid to reinstitute coverage of GLP-1s for weight management. NC Medicaid (NCDHHS), Dec 19, 2025.
  55. Pharmacy provider manual: exclusions. North Dakota HHS, Jun 1, 2026.
  56. OAC 5160-9-03. Ohio Laws and Administrative Rules, Feb 16, 2024.
  57. Metabolic disorders PA criteria. Oklahoma Health Care Authority, Oct 1, 2026.
  58. Weight management drugs PA criteria. Oregon Health Plan (orpdl.org), Mar 1, 2026.
  59. Medical Assistance Bulletin: GLP-1 coverage changes. Pennsylvania DHS, Nov 24, 2025.
  60. GLP-1 coverage change effective Oct 1, 2026. Rhode Island EOHHS, Aug 5, 2026.
  61. P&T committee minutes, Nov 5, 2025. South Carolina DHHS, Nov 5, 2025.
  62. Pharmacy services billing manual. South Dakota DSS, May 26, 2026.
  63. Provider notice: obesity management agents. TennCare (OptumRx), Aug 1, 2025.
  64. Weight management drugs. Texas HHSC Vendor Drug Program, Oct 18, 2026.
  65. GLP-1 medications for weight-related comorbidities: PA form. Utah DHHS, Jun 1, 2026.
  66. Vermont Medicaid PDL, Oct 2, 2026. Vermont DVHA, Oct 2, 2026.
  67. Weight loss management service authorization form. Virginia DMAS, Jul 1, 2026.
  68. Semaglutide (Wegovy) policy. Washington HCA, Feb 1, 2026.
  69. Zepbound PA criteria. West Virginia BMS, Jul 1, 2025.
  70. ForwardHealth Update 2026-15. Wisconsin DHS (ForwardHealth), Jun 2026.
  71. Wyoming Medicaid provider manual, revision 26. Wyoming Department of Health, Oct 10, 2024.

This page is general information, not medical advice. Talk with a licensed clinician about your own care.

See GLP-1 self-pay prices